Valuation: Compass Therapeutics, Inc.

Market Cap 42Cr 37Cr 34Cr 31Cr 60Cr 4.02TCr 61Cr 406.84Cr 159.55Cr 1.98TCr 158.2Cr 154.77Cr 6.84TCr P/E 2026 *
-5.37x
P/E 2027 * -5.04x
Enterprise Value 27Cr 24Cr 22Cr 20Cr 38Cr 2.59TCr 39Cr 262.02Cr 102.76Cr 1.27TCr 101.89Cr 100Cr 4.41TCr EV / Sales 2026 *
-132x
EV / Sales 2027 * 11.5x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
1 day-1.28%
1 week+5.96%
Current month+5.48%
1 month+14.36%
3 months-57.22%
6 months-55.32%
Current year-56.98%
1 week 2.15
Extreme 2.15
2.36
1 month 1.88
Extreme 1.88
2.36
Current year 1.61
Extreme 1.61
6.88
1 year 1.61
Extreme 1.61
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 28/05/2024
Director of Finance/CFO 54 09/12/2024
Chief Tech/Sci/R&D Officer 50 01/01/2026
Director TitleAgeSince
Director/Board Member 65 01/01/2014
Director/Board Member 64 01/01/2015
Chairman 61 01/01/2015
Date Insider Type Main position Quantity % Market Cap.
29/04Buy

Controller/Auditor

15,000 0.0083%
29/04Buy

General Counsel

25,000 0.0139%
08/02Tax

Chief Executive Officer

36,687 0.0206%
Change 5-day change 1-year change 3-year change Capi.($)
-1.28%+5.96%-12.83%-20.89% 42Cr
-0.38%+0.40%+71.69%+128.83% 5.67TCr
+4.91%-3.30%+71.97%+92.14% 5.13TCr
+1.48%+10.52%+23.01%+495.47% 2.53TCr
-0.59%-1.00%-16.73%-12.99% 2.37TCr
+3.93%+7.11%+44.20%-1.96% 1.87TCr
+2.01%+7.22%+41.55%-24.93% 1.77TCr
-6.84%+4.81%+201.88%+348.11% 1.77TCr
-0.92%+8.90%+38.48% - 1.43TCr
+1.76%+5.82%+31.23%+195.70% 1.41TCr
Average +0.41%+3.84%+49.45%+133.28% 2.4TCr
Weighted average by Cap. +1.05%+2.17%+58.64%+144.87%

Financials

2026 *2027 *
Net sales -20.57L -18L -16.58L -15.35L -29.14L -20Cr -29.66L -1.99Cr -77.89L -9.65Cr -77.23L -75.55L -33Cr 2.53Cr 2.21Cr 2.04Cr 1.89Cr 3.58Cr 241.01Cr 3.64Cr 24Cr 9.57Cr 118.51Cr 9.49Cr 9.28Cr 410.29Cr
Net income -8.24Cr -7.21Cr -6.65Cr -6.15Cr -12Cr -786.27Cr -12Cr -80Cr -31Cr -386.64Cr -31Cr -30Cr -1.34TCr -8.96Cr -7.84Cr -7.22Cr -6.68Cr -13Cr -854.28Cr -13Cr -86Cr -34Cr -420.09Cr -34Cr -33Cr -1.45TCr
Net Debt -15Cr -13Cr -12Cr -11Cr -21Cr -1.43TCr -22Cr -144.82Cr -57Cr -703.52Cr -56Cr -55Cr -2.44TCr -13Cr -12Cr -11Cr -9.85Cr -19Cr -1.26TCr -19Cr -127.44Cr -50Cr -619.1Cr -50Cr -48Cr -2.14TCr
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
09/26/09 $2.310 -1.28% 19,69,776
08/26/08 $2.340 +0.86% 38,81,914
07/26/07 $2.320 +1.31% 32,12,752
06/26/06 $2.290 +0.88% 24,81,789
02/26/02 $2.270 +4.13% 29,39,846
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.340USD
Average target price
8.500USD
Spread / Average Target
+263.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPX Stock